Therefore, patients with type 2 diabetes should be treated to improve relevant glucose and insulin indices then, appropriate hypoglycemic drugs should be selected in combination with their economic status and family background, to improve the pertinent treatment. This evidence concerns the gene INS and type 2 diabetes mellitus.